Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population
JAMA · 24.01.2023 · 329 (4) · 318
DOI: 10.1001/jama.2022.24836 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA, erschienen am 24.01.2023. Verfasst von David B Beck und 17 weiteren Autor:innen. Beteiligte Einrichtung: National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Ubiquitin-Activating Enzymes, Skin Diseases, Genetic. Die Arbeit wurde bisher 263-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Importance VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome is a disease with rheumatologic and hematologic features caused by somatic variants in UBA1 . Pathogenic variants are associated with a broad spectrum of clinical manifestations. Knowledge of prevalence, penetrance, and clinical characteristics of this disease have been limited by ascertainment biases based on known phenotypes.
Objective
To determine the prevalence of pathogenic variants in UBA1 and associated clinical manifestations in an unselected population using a genomic ascertainment approach. Design, Setting, and Participants This retrospective observational study evaluated UBA1 variants in exome data from 163 096 participants within the Geisinger MyCode Community Health Initiative. Clinical phenotypes were determined from Geisinger electronic health record data from January 1, 1996, to January 1, 2022. Exposures Exome sequencing was performed. Main Outcomes and Measures Outcome measures included prevalence of somatic UBA1 variation; presence of rheumatologic, hematologic, pulmonary, dermatologic, and other findings in individuals with somatic UBA1 variation on review of the electronic health record; review of laboratory data; bone marrow biopsy pathology analysis; and in vitro enzymatic assays.
Results
In 163 096 participants (mean age, 52.8 years; 94% White; 61% women), 11 individuals harbored likely somatic variants at known pathogenic UBA1 positions, with 11 of 11 (100%) having clinical manifestations consistent with VEXAS syndrome (9 male, 2 female). A total of 5 of 11 individuals (45%) did not meet criteria for rheumatologic and/or hematologic diagnoses previously associated with VEXAS syndrome; however, all individuals had anemia (hemoglobin: mean, 7.8 g/dL; median, 7.5 g/dL), which was mostly macrocytic (10/11 [91%]) with concomitant thrombocytopenia (10/11 [91%]). Among the 11 patients identified, there was a pathogenic variant in 1 male participant prior to onset of VEXAS-related signs or symptoms and 2 female participants had disease with heterozygous variants. A previously unreported UBA1 variant (c.1861A>T; p.Ser621Cys) was found in a symptomatic patient, with in vitro data supporting a catalytic defect and pathogenicity. Together, disease-causing UBA1 variants were found in 1 in 13 591 unrelated individuals (95% CI, 1:7775-1:23 758), 1 in 4269 men older than 50 years (95% CI, 1:2319-1:7859), and 1 in 26 238 women older than 50 years (95% CI, 1:7196-1:147 669). Conclusions and Relevance This study provides an estimate of the prevalence and a description of the clinical manifestations of UBA1 variants associated with VEXAS syndrome within a single regional health system in the US. Additional studies are needed in unselected and genetically diverse populations to better define general population prevalence and phenotypic spectrum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
- Center for Human Genetics and Genomics, New York University School of Medicine.
- Division of Rheumatology, Department of Medicine, New York University School of Medicine.
- Geisinger Research, North Bethesda, Maryland.
- Department of Molecular and Functional Genomics, Geisinger, Danville, Pennsylvania.
- Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
Förderung
- NIGMS NIH HHS
- NIAMS NIH HHS
Zitieren
APA
Beck, D. B., Bodian, D. L., Shah, V., Mirshahi, U. L., Kim, J., Ding, Y., Magaziner, S. J., Strande, N. T., Cantor, A., Haley, J. S., Cook, A., Hill, W., Schwartz, A. L., Grayson, P. C., Ferrada, M. A., Kastner, D. L., Carey, D. J., & Stewart, D. R. (2023). Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. JAMA, 329(4), 318. https://doi.org/10.1001/jama.2022.24836
Vancouver
Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. JAMA. 2023;329(4):318. doi:10.1001/jama.2022.24836
BibTeX
@article{Beck2023,
author = {Beck, David B and Bodian, Dale L and Shah, Vandan and Mirshahi, Uyenlinh L and Kim, Jung and Ding, Yi and Magaziner, Samuel J and Strande, Natasha T and Cantor, Anna and Haley, Jeremy S and Cook, Adam and Hill, Wesley and Schwartz, Alan L and Grayson, Peter C and Ferrada, Marcela A and Kastner, Daniel L and Carey, David J and Stewart, Douglas R},
title = {Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population},
journal = {JAMA},
year = {2023},
volume = {329},
number = {4},
pages = {318},
doi = {10.1001/jama.2022.24836}
}
EUVIMED